A more recent development was the approval of the combination of atezolizumab (anti-PD-L1 antibody) and bevacizumab (anti-VEGF antibody) as first-line therapy for patients with unresectable or metastatic HCC, due to its superior efficacy compared to sorafenib in a phase III clinical trial (12). Here, VEGFA is linked to hepatocellular carcinoma.